Regeneration medtech company Tissue Regenix Group has agreed a deal with German distributor 2med GmbH.
It means the Hamburg-based operator, which specialises in products for the surgical and orthobiological treatments of the musculoskeletal system, will use Tissue Regenix's patented dCell technology in its OrthoPure XT which is used in cruciate and knee ligament reconstruction. At the moment, the multi-year deal covers Germany but there is potential for expansion into other territories that 2med covers.
Thomas Guenther, commercial director at 2med, said: "2med are delighted to be representing OrthoPure XT in Germany. The initial feedback from our knee surgeons is very positive and we are excited to offer this new, easy to use option for German patients with damaged ACL and other knee ligaments."
Read more: Wellness brand Moodbeam acquired by fellow Hull firm The 55 Group
Daniel Lee, chief executive officer of Tissue Regenix Group, added: "Following the success of our partnership with Geistlich Biomaterials Italia, that we announced in March 2022, we are pleased to have signed this distribution agreement with 2med for Germany. 2med's work with doctors and patients, to offer advanced treatments and minimise rehabilitation times, are aligned with this innovative product and has made 2med one of the leading specialist dealers in Germany. We look forward to working with 2med and continuing to expand the use of OrthoPure XT across Europe."
2med supplies surgical and biological therapy procedures for the shoulder, knee, foot and ankle. Its treatments support an active and independent lifestyle.
READ NEXT:
